; Skip to content

Idiopathic Pulmonary Fibrosis (IPF) & GERD

Search Clinical Trials

Trial Objectives


GERD & IPFThe purpose of this study is to measure and accurately identify the presence and severity of gastroesphageal reflux disease (GERD), commonly called acid reflux, in idiopathic pulmonary fibrosis (IPF) patients using the Supraglottic Index (SGI). The study also will determine if stomach reflux or abnormal swallowing are associated with the progression of IPF.

Who Can Participate


Individuals ages 40-95 who have been diagnosed with IPF may be eligible to participate.

Age: 40-95 Gender Any

Estimated Time Commitment


5 visits over a 6-month period, visits are every 3 months

Payment & Reimbursement


Payment Provided

Travel Reimbursement Not Available

Trial Contact


For more information, contact:

Maria Saucedo

Maria Saucedo
303.398.1790

Request More Information

Trial Location


National Jewish Main Campus, Denver, CO

Trial Sponsors


Boehringer Ingelheim

Principal Investigators

Matthew Koslow

Matthew Koslow, MD

Request more Information

By completing this form, you agree to learn more about this study and see if you qualify.

I would also like to receive periodic emails with health information, news and clinical research updates from National Jewish Health required